The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of docetaxel (D), cisplatinum (C), and continuous capecitabine (CAP) (TCX) in advanced esophagogastric cancer (AEC).
Simon Gollins
Honoraria - Roche
Arwel Lloyd
No relevant relationships to disclose
Jackie Morris
No relevant relationships to disclose
Nick Smith
No relevant relationships to disclose
Brian Haylock
No relevant relationships to disclose
David Smith
No relevant relationships to disclose
Angel Garcia-Alonso
No relevant relationships to disclose